Church & Dwight vs Johnson & Johnson
Side-by-side comparison of AI visibility scores, market position, and capabilities
Consumer goods company with $6B revenue; Arm & Hammer, OxiClean, Trojan, and Waterpik portfolio targeting mid-tier value-oriented consumers competing with P&G and Colgate-Palmolive.
About
Church & Dwight is a consumer packaged goods company producing personal care, household, and specialty products across well-known brands including Arm & Hammer (baking soda-based cleaning and dental products), OxiClean (laundry stain remover), Trojan condoms, Vitafusion gummies vitamins, Waterpik water flosser, Batiste dry shampoo, and Zicam cold remedies. Listed on NYSE (NYSE: CHD) and headquartered in Ewing, New Jersey, Church & Dwight generates approximately $6 billion in annual revenue and has demonstrated consistent organic growth through its "power brand" portfolio management strategy.\n\nChurch & Dwight's brand portfolio spans multiple consumer need categories: Arm & Hammer (baking soda as a platform for toothpaste, cat litter, laundry detergent, and odor eliminator), personal care (Waterpik, Batiste dry shampoo, XTRA laundry), vitamins (Vitafusion and L'il Critters gummy vitamins), sexual health (Trojan, Natalist fertility), and household products (OxiClean, Kaboom). The Arm & Hammer baking soda brand's versatility across multiple product categories creates unique brand leverage.\n\nIn 2025, Church & Dwight has been one of the more consistent performers in consumer staples — the company targets value-oriented consumers in mid-tier price positions (above private label, below premium brands) across its categories. It competes with Procter & Gamble, Colgate-Palmolive, and Henkel for household and personal care market share. The company's 2025 strategy focuses on expanding its international distribution (historically US-focused, with international growth potential for brands like Batiste and Waterpik), growing Vitafusion in the wellness supplement category, and pursuing selective brand acquisitions in premium personal care niches.
FY2024 Sales: $88.8B (+4.3%) | Net Profit: $14.1B (+5.6%) | EPS: $5.79 | Adjusted EPS: $9.98 | FY2025 Guidance: Operational Sales Growth 2.5-3.5%, Adj EPS $10.75-$10.95 (+8.7% midpoint)
About
Johnson & Johnson is one of the world's largest healthcare companies, founded in 1886 by brothers Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson in New Brunswick, New Jersey, where the company remains headquartered. Established to manufacture ready-to-use surgical dressings at a time when post-operative infection was a leading cause of surgical mortality, J&J was built on the scientific principles of antiseptic surgery advocated by Joseph Lister. The company trades on the NYSE under ticker JNJ and has evolved over 135+ years from a consumer health products manufacturer into a focused MedTech and pharmaceutical enterprise, completing the spinoff of its consumer health segment (Kenvue) in 2023.\n\nJohnson & Johnson now operates through two segments: Innovative Medicine and MedTech. Innovative Medicine encompasses oncology, immunology, neuroscience, infectious disease, and cardiovascular pharmaceutical products — including blockbusters Darzalex, Stelara, Tremfya, and Rybrevant. The MedTech segment includes surgical robotics (Ottava platform in development), electrophysiology (Abiomed, Biosense Webster), orthopedics (DePuy Synthes), and surgery systems, serving hospitals and surgical centers worldwide. Following the Kenvue separation, J&J is a pure-play healthcare technology and pharmaceutical company with significantly higher growth and margin profiles than its historical blended consumer-pharma-medtech structure.\n\nJohnson & Johnson reported FY2024 sales of $88.8 billion, up 4.3% year over year, with net profit of $14.1 billion, up 5.6%. The company's Innovative Medicine segment continues to grow driven by oncology and immunology portfolio strength, while MedTech benefits from procedure volume recovery and robotic surgery adoption. J&J's scale, R&D pipeline depth, and global commercial infrastructure — spanning more than 60 countries — position it as one of the two or three most consequential healthcare enterprises globally, with a patent portfolio, clinical trial network, and regulatory expertise that are nearly impossible to replicate.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.